---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-25-077373"
form_type: "8-K"
ticker: "EYPT"
cik: "0001314102"
company_name: "EyePoint, Inc."
filed_at: "2025-05-27T23:59:59+00:00"
generated_at: "2026-05-20T10:17:48.725622+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# EyePoint completes Phase 3 LUGANO enrollment for DURAVYU wet AMD; topline data mid-2026

## Summary
- Over 400 patients enrolled/randomized in seven months, one of fastest Phase 3 wet AMD trials.
- LUCIA trial 60% randomized; enrollment completion expected Q3 2025.
- Topline 56-week LUGANO data mid-2026; LUCIA data in H2 2026.
- Phase 3 trials are randomized, double-masked, non-inferiority vs. aflibercept; DURAVYU dosed every 6 months.
- DURAVYU is sustained-delivery vorolanib (TKI); potential first sustained-release TKI for wet AMD.

## SEC filing metadata
- accession: 0000950170-25-077373
- form_type: 8-K
- ticker: EYPT
- cik: 0001314102
- company_name: EyePoint, Inc.
- filed_at: 2025-05-27T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1314102/000095017025077373/0000950170-25-077373-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1314102/000095017025077373/eypt-20250527.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-25-077373
- JSON: https://secwatch.observer/filing/0000950170-25-077373.json
- Plain text: https://secwatch.observer/filing/0000950170-25-077373.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.